Compare VSAT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | EVO |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 1.1B |
| IPO Year | 1996 | N/A |
| Metric | VSAT | EVO |
|---|---|---|
| Price | $69.52 | $2.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $59.80 | $7.00 |
| AVG Volume (30 Days) | ★ 2.3M | 40.1K |
| Earning Date | 05-19-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.32 | $1.37 |
| Revenue Next Year | $3.57 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.28 | $2.31 |
| 52 Week High | $89.79 | $4.42 |
| Indicator | VSAT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 51.17 |
| Support Level | $67.20 | $2.88 |
| Resistance Level | $89.79 | $3.82 |
| Average True Range (ATR) | 5.88 | 0.06 |
| MACD | -1.43 | 0.01 |
| Stochastic Oscillator | 12.60 | 73.17 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.